TR199900520A3 - Bilesik ve kullanimi. - Google Patents

Bilesik ve kullanimi.

Info

Publication number
TR199900520A3
TR199900520A3 TR1999/00520A TR9900520A TR199900520A3 TR 199900520 A3 TR199900520 A3 TR 199900520A3 TR 1999/00520 A TR1999/00520 A TR 1999/00520A TR 9900520 A TR9900520 A TR 9900520A TR 199900520 A3 TR199900520 A3 TR 199900520A3
Authority
TR
Turkey
Prior art keywords
usage
compound
Prior art date
Application number
TR1999/00520A
Other languages
English (en)
Other versions
TR199900520A2 (tr
Inventor
Mary Edmeades Lorraine
Arthur Griffith-Skinner Nigel
Anthony Hill Derek
Thronton Hill Graham
William Packham Terence
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199900520(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of TR199900520A3 publication Critical patent/TR199900520A3/tr
Publication of TR199900520A2 publication Critical patent/TR199900520A2/tr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
TR1999/00520A 1998-06-10 1999-03-10 Bilesik ve kullanimi. TR199900520A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (2)

Publication Number Publication Date
TR199900520A3 true TR199900520A3 (tr) 2000-01-21
TR199900520A2 TR199900520A2 (tr) 2000-01-21

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00520A TR199900520A2 (tr) 1998-06-10 1999-03-10 Bilesik ve kullanimi.

Country Status (31)

Country Link
US (1) US6333198B1 (tr)
EP (2) EP1170588A1 (tr)
JP (1) JP2989189B1 (tr)
KR (1) KR100322354B1 (tr)
CN (2) CN1238454A (tr)
AP (3) AP9901481A0 (tr)
AR (1) AR014074A1 (tr)
AT (1) ATE218552T1 (tr)
AU (1) AU2031999A (tr)
BR (1) BR9900984A (tr)
CA (1) CA2265194C (tr)
DE (1) DE69901656T2 (tr)
DK (1) DK0963980T3 (tr)
EA (1) EA000666B1 (tr)
ES (1) ES2178342T3 (tr)
GB (1) GB9812413D0 (tr)
HR (1) HRP990074A2 (tr)
HU (1) HUP9900592A3 (tr)
ID (1) ID22957A (tr)
MA (1) MA24777A1 (tr)
NO (2) NO991151L (tr)
NZ (1) NZ334590A (tr)
PE (1) PE20000332A1 (tr)
PL (1) PL331870A1 (tr)
PT (1) PT963980E (tr)
SG (1) SG85628A1 (tr)
SI (1) SI0963980T1 (tr)
TR (1) TR199900520A2 (tr)
UY (1) UY25946A1 (tr)
YU (1) YU12399A (tr)
ZA (1) ZA991951B (tr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
GB2372988B (en) * 2000-01-03 2004-04-07 Rpg Life Sciences Ltd A process for the preparation of 6-(2,3-Dichlorophenyl)-1,2,4- Triazine-3,5-Diamine, commonly known as Lamotrigine
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
BR0116554A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
WO2002053538A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amlodipine fumarate
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
MXPA03005884A (es) 2000-12-29 2005-04-08 Pfizer Ltd Hemimaleato de amlodipina.
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
ES2243553T3 (es) 2000-12-29 2005-12-01 Pfizer Limited Procedimiento para preparar maleato de amlodipina.
BR0116553A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para tratamento de angina ou hipertensão, processo, processo para tratamento ou prevenção de angina ou hipertensão, composição de ingredientes farmaceuticamente ativos, composição farmacêutica para tratamento ou prevenção de angina ou hipertensão e processo para tratar ou prevenir angina ou hipertensão
GB2371862B (en) * 2000-12-29 2004-07-14 Bioorg Bv Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
DE10134980C2 (de) * 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
EP1601658A1 (en) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20050187244A1 (en) * 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
EP1708708A1 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
EP1646612B1 (en) * 2004-04-21 2009-07-01 Teva Pharmaceutical Industries Ltd Processes for preparing montelukast sodium
MXPA06005659A (es) 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
WO2005105771A1 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
ATE407111T1 (de) * 2004-06-28 2008-09-15 Teva Pharm Fine Chemicals Srl Isolierte atomoxetinverunreinigung, verfahren zur herstellung von atomoxetinverunreinigungen und deren verwendung als referenzstandards
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
US20060069150A1 (en) * 2004-07-20 2006-03-30 Sandor Molnar Processes for preparation of crystalline mycophenolate sodium
CA2568629A1 (en) * 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
JP2007513074A (ja) * 2004-09-04 2007-05-24 テバ ファーマシューティカル インダストリーズ リミティド 単離されたバラシクロビル不純物、バラシクロビル不純物の調製方法および参照標準としての使用
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
CA2579997A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
JP2007514777A (ja) * 2004-10-19 2007-06-07 テバ ファーマシューティカル インダストリーズ リミティド テガセロッドマレエートの精製
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
CA2591666A1 (en) * 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
KR101020024B1 (ko) * 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
EP1866295A2 (en) * 2005-02-24 2007-12-19 Teva Pharmaceutical Industries Ltd Processes for the preparation of linezolid intermediate
CA2599478A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the purification of duloxetine hydrochloride
JP2008501721A (ja) * 2005-04-05 2008-01-24 テバ ファーマシューティカル ファイン ケミカルズ ソチエタ レスポンサビリタ リミテ 安定性アトモキセチン塩酸塩、その調製方法及びその安定性の分析的調節
EP1866275A1 (en) * 2005-04-06 2007-12-19 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
CA2603215A1 (en) * 2005-04-11 2006-10-19 Teva Pharmaceutical Industries Ltd. Process for making (s)-pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
US7462737B2 (en) * 2005-05-10 2008-12-09 Teva Pharmaceutical Industries Ltd. Pregabalin free of isobutylglutaric acid and a process for preparation thereof
WO2006121557A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
ATE486841T1 (de) * 2005-05-10 2010-11-15 Teva Pharma Verfahren zur herstellung von pregabalin und salzen daraus
US20070043241A1 (en) * 2005-05-10 2007-02-22 Lilach Hedvati Optical resolution of 3-carbamoylmethyl-5-methylhexanoic acid
CA2605736A1 (en) 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Purification of cinacalcet
KR20080015436A (ko) * 2005-06-27 2008-02-19 시코르, 인크. 아나스트로졸 합성 방법 및 이의 중간 생성물 중 하나의정제 방법
CA2606945A1 (en) * 2005-06-27 2007-01-04 Sicor, Inc. An impurity of anastrozole intermediate, and uses thereof
KR20090015186A (ko) * 2005-07-05 2009-02-11 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트의 정제
WO2007022488A2 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
KR20070087596A (ko) * 2005-09-19 2007-08-28 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ)-(+)-3-(아미노메틸)-5-메틸헥산산의 비대칭 합성
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
EP1966179A2 (en) * 2005-12-27 2008-09-10 Teva Pharmaceutical Industries Ltd Darifenacin hydrobromide composition substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
CA2644819A1 (en) * 2006-03-27 2007-11-08 Teva Pharmaceutical Fine Chemicals S.R.L. Process for preparing memantine hydrochloride substantially free of impurities
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
US7462738B2 (en) * 2006-05-24 2008-12-09 Teva Pharmaceutical Industries Ltd. Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
EP1912931A2 (en) * 2006-05-31 2008-04-23 Teva Pharmaceutical Industries Ltd. Preparation of (s)-pregabalin-nitrile
KR20080036060A (ko) * 2006-05-31 2008-04-24 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린의 중간체의 제조에 효소 분할을 이용하는 방법
KR20080069571A (ko) * 2006-06-29 2008-07-28 테바 파마슈티컬 인더스트리즈 리미티드 산 대사산물 생성의 조절
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
WO2008019798A1 (en) * 2006-08-14 2008-02-21 Lonza Ag A process for the preparation of lamotrigine
US20080242877A1 (en) * 2007-02-26 2008-10-02 Vinod Kumar Kansal Intermediates and processes for the synthesis of Ramelteon
MX2008014759A (es) * 2007-03-22 2009-03-09 Teva Pharma Sintesis del acido (s)-(+)-3-(aminometil)-5-metil hexanoico.
US20080254520A1 (en) * 2007-04-11 2008-10-16 Eva Gulyas Method for reducing impurity level in mycophenolic acid fermentation
EP2098519A1 (en) * 2007-05-31 2009-09-09 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
KR20090101462A (ko) * 2007-10-03 2009-09-28 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
EP2508523B2 (en) * 2007-10-23 2019-04-17 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
US20090281176A1 (en) * 2007-11-01 2009-11-12 Vinod Kumar Kansal Process for the synthesis of ramelteon and its intermediates
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
WO2009151494A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2011121452A2 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
CN110467560B (zh) 2018-05-09 2025-11-25 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD151309A5 (de) 1979-06-01 1981-10-14 Wellcome Found Verfahren zur herstellung von substituierten aminotriazinen
DE3062603D1 (en) 1979-06-01 1983-05-11 Wellcome Found 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
EP0800520B1 (en) * 1994-12-30 2002-06-19 The Wellcome Foundation Limited Process for the preparation of lamotrigine
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Also Published As

Publication number Publication date
CA2265194C (en) 2000-10-10
DK0963980T3 (da) 2002-09-16
CN1306210A (zh) 2001-08-01
JP2989189B1 (ja) 1999-12-13
NO20032753D0 (no) 2003-06-17
EP0963980A3 (en) 2000-05-31
SG85628A1 (en) 2002-01-15
PL331870A1 (en) 1999-12-20
DE69901656D1 (de) 2002-07-11
KR20000005611A (ko) 2000-01-25
GB9812413D0 (en) 1998-08-05
HUP9900592A2 (hu) 2000-04-28
EA000666B1 (ru) 2000-02-28
ATE218552T1 (de) 2002-06-15
EA199900159A1 (ru) 1999-12-29
JP2000009714A (ja) 2000-01-14
YU12399A (sh) 2002-08-12
AP0102286A0 (en) 2000-09-10
MA24777A1 (fr) 1999-10-01
EP0963980A2 (en) 1999-12-15
AP9901481A0 (en) 1999-03-31
PT963980E (pt) 2002-10-31
UY25946A1 (es) 2000-12-29
EP0963980B1 (en) 2002-06-05
BR9900984A (pt) 2000-05-02
NZ334590A (en) 2000-07-28
EP1170588A1 (en) 2002-01-09
CN1238454A (zh) 1999-12-15
NO991151L (no) 1999-12-13
US6333198B1 (en) 2001-12-25
HU9900592D0 (en) 1999-04-28
ES2178342T3 (es) 2002-12-16
NO991151D0 (no) 1999-03-10
HUP9900592A3 (en) 2002-04-29
AP2001002286A0 (en) 2001-12-31
DE69901656T2 (de) 2003-01-30
NO20032753L (no) 1999-12-13
ID22957A (id) 1999-12-23
TR199900520A2 (tr) 2000-01-21
KR100322354B1 (ko) 2002-02-07
SI0963980T1 (en) 2002-12-31
PE20000332A1 (es) 2000-04-10
AU2031999A (en) 2000-01-06
ZA991951B (en) 1999-08-16
HRP990074A2 (en) 2000-10-31
AR014074A1 (es) 2001-01-31

Similar Documents

Publication Publication Date Title
TR199900520A3 (tr) Bilesik ve kullanimi.
TR199900531A3 (tr) Pirazolopirimidinler ve pirazolotriazinler.
CU23049A3 (es) Dihidropirimidinas.
DK1084104T3 (da) Nitrogenoxidsynthaseinhibitorer
DE59914158D1 (de) Metallocenmonohalogenide
ATE341990T1 (de) Sigmidoskop
DE59911453D1 (de) Aktivkohlefilter
DE59912371D1 (de) Gleitschalungsfertiger
DE59902874D1 (de) Buchsenkontakt
DE59901560D1 (de) Retrograder tibianagel
IT1312540B1 (it) Composto.
DE59906931D1 (de) Exzenterzahnradgetriebe
DE59911683D1 (de) Fahrzeugschliessanlage
DE59908968D1 (de) Benzoylpyridazine
DE59903966D1 (de) Exzenterzahnradgetriebe
DE59913393D1 (de) Fadenchangierung
ID28624A (id) Turunan 2-fenilpiran-4-on
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59908057D1 (de) Underdruckhandhabungseinrichung
DE59808995D1 (de) Endomikroskopsystem
DE59807217D1 (de) Nadellager
DE19842103B4 (de) Stanznietzuführung
DE69808524D1 (de) Refinerplattensegment
DE59902088D1 (de) Achrathermer Reimager